Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 9;12(1):2208.
doi: 10.1038/s41598-022-05688-9.

Long-term risk of adverse outcomes according to atrial fibrillation type

Collaborators, Affiliations

Long-term risk of adverse outcomes according to atrial fibrillation type

Steffen Blum et al. Sci Rep. .

Abstract

Sustained forms of atrial fibrillation (AF) may be associated with a higher risk of adverse outcomes, but few if any long-term studies took into account changes of AF type and co-morbidities over time. We prospectively followed 3843 AF patients and collected information on AF type and co-morbidities during yearly follow-ups. The primary outcome was a composite of stroke or systemic embolism (SE). Secondary outcomes included myocardial infarction, hospitalization for congestive heart failure (CHF), bleeding and all-cause mortality. Multivariable adjusted Cox proportional hazards models with time-varying covariates were used to compare hazard ratios (HR) according to AF type. At baseline 1895 (49%), 1046 (27%) and 902 (24%) patients had paroxysmal, persistent and permanent AF and 3234 (84%) were anticoagulated. After a median (IQR) follow-up of 3.0 (1.9; 4.2) years, the incidence of stroke/SE was 1.0 per 100 patient-years. The incidence of myocardial infarction, CHF, bleeding and all-cause mortality was 0.7, 3.0, 2.9 and 2.7 per 100 patient-years, respectively. The multivariable adjusted (a) HRs (95% confidence interval) for stroke/SE were 1.13 (0.69; 1.85) and 1.27 (0.83; 1.95) for time-updated persistent and permanent AF, respectively. The corresponding aHRs were 1.23 (0.89, 1.69) and 1.45 (1.12; 1.87) for all-cause mortality, 1.34 (1.00; 1.80) and 1.30 (1.01; 1.67) for CHF, 0.91 (0.48; 1.72) and 0.95 (0.56; 1.59) for myocardial infarction, and 0.89 (0.70; 1.14) and 1.00 (0.81; 1.24) for bleeding. In this large prospective cohort of AF patients, time-updated AF type was not associated with incident stroke/SE.

PubMed Disclaimer

Conflict of interest statement

SB: research grant from the Mach-Gaensslen Foundation outside the submitted work; DS: speaker fees from Biosense Webster, Daiichi-Sankyo, Boehringer Ingelheim, Bristol-Myers Squibb, and Bayer; consultancy honoraria from Biosense Webster; JHB: grants from the Swiss National Foundation of Science, The Swiss Heart Foundation, grants from Bayer, lecture fees from Sanofi Aventis and Amgen, to the institution outside the submitted work; RK: grants from Biotronik, BiosenseWebster, Boston Scientific, Medtronic, and Abbott; LHB: grants from the Swiss National Science Foundation (PBBSB-116873, 33CM30-124119, 32003B-156658; Berne, Switzerland), The Swiss Heart Foundation (Berne, Switzerland, and the University of Basel (Basel, Switzerland); unrestricted research grant from AstraZeneca, and consultancy or advisory board fees or speaker’s honoraria from Amgen, Bayer, Bristol-Myers Squibb, and Claret Medical, and travel grants from AstraZeneca and Bayer; NR: grant from the Swiss Heart Foundation; MK: served on the speakers’ bureau for Boston Scientific, St. Jude Medical and Biotronik; lecture/consulting fees from Sorin, Boehringer Ingelheim, Bayer, Sanofi Aventis, Novartis, Medtronic, Pfizer-BMS; unrestricted grants from Bayer and Pfizer-BMS; proctor for Medtronic (Cryoballoon); CS: speaker honoraria from Biosense Webster, Boston Scientific and Medtronic; research grants from Biosense Webster, Daiichi-Sankyo, and Medtronic; proctor for Medtronic (Cryoballoon); DC: consultant/speaker fees from Servier Canada outside of the submitted work. No other author has any conflict of interest to declare.

References

    1. Kirchhof P, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart. J. 2016;37:2893–2962. doi: 10.1093/eurheartj/ehw210. - DOI - PubMed
    1. Chen HS, Wen JM, Wu SN, Liu JP. Catheter ablation for paroxysmal and persistent atrial fibrillation. Cochrane Database Syst. Rev. 2012 doi: 10.1002/14651858.CD007101.pub2. - DOI - PMC - PubMed
    1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991;22:983–988. doi: 10.1161/01.STR.22.8.983. - DOI - PubMed
    1. Wang TJ, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation. 2003;107:2920–2925. doi: 10.1161/01.CIR.0000072767.89944.6E. - DOI - PubMed
    1. Conen D, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA. 2011;305:2080–2087. doi: 10.1001/jama.2011.659. - DOI - PMC - PubMed

Publication types

MeSH terms